Eltrombopag plus cyclosporine in refractory immune thrombocytopenia: a single-center study

BACKGROUND: With the development of thrombopoietin receptor agonists, the prognosis of immune thrombocytopenia (ITP) in patients in whom there was a poor response to first-line treatment has greatly improved. However, there are still some patients who are refractory to eltrombopag. OBJECTIVES: To ex...

Descripción completa

Detalles Bibliográficos
Autores principales: Hong, Yilei, Shen, Yingying, Liu, Qi, Dong, Jingjie, Xiang, Jingjing, Shen, Yiping, Wu, Liqiang, Zhou, Yuhong, Ye, Baodong, Wu, Dijiong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10339056/
https://www.ncbi.nlm.nih.gov/pubmed/37456916
http://dx.doi.org/10.1016/j.rpth.2023.100279

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10339056/
https://www.ncbi.nlm.nih.gov/pubmed/37456916
http://dx.doi.org/10.1016/j.rpth.2023.100279

Ejemplares similares